Study of Dapagliflozin to Reduce Heart Damage After Acute Heart Attack in Adults with Left Ventricular Dysfunction

What this Trial Is About

Researchers are evaluating the effects of dapagliflozin, a sodium-glucose co-transporter 2 SGLT2 inhibitor, on heart patients who have had an acute myocardial infarction AMI and have left ventricular LV dysfunction. The study aims to assess whether dapagliflozin can reduce cardiac remodeling, which is linked to heart failure and cardiovascular death. This phase III, randomized, double-blind trial focuses on patients with confirmed AMI and reduced ejection fraction LVEF 64 45% after percutaneous coronary intervention PCI. Participants will be randomly assigned to receive either dapagliflozin 10 mg daily or a placebo for six months, alongside standard heart failure care as per current guidelines. Treatment starts soon after hospital admission. The study includes four main visits baseline and randomization, discharge from the cardiac intensive care unit, a 3-month follow-up, and a 6-month final visit. Heart function will be assessed by transthoracic echocardiography TTE at the start and end of the study, with all imaging analyzed centrally by independent cardiologists. During the trial, patients will be monitored for treatment tolerance through scheduled visits and phone calls to confirm no additional SGLT2 inhibitors are taken. Researchers will measure changes in heart function parameters such as left ventricular ejection fraction and left atrium volume. Secondary outcomes include heart volume changes, strain measurements, hospital stay duration, mortality, heart failure worsening, readmissions, biomarker levels, body weight, and adverse events. The total participation lasts six months from randomization.

DAPAgliflozine to Attenuate Cardiac RemOdeling afTEr aCuTe myOcardial Infarction